Machine Learning

The wealth tech leader unveils its InsightX platform and AI Innovation Lab, designed to make advanced analytics accessible to all financial professionals.

As AI rewires public thought, a new platform launches a training system to build cognitive independence and help users think clearly in a manipulative world.

With new funding led by Telegraph Hill Partners, Kytopen is scaling its Flowfect® tech to make advanced cell therapies faster, cheaper, and more accessible.

Language services leader GLOBO hires a new CTO with deep AI expertise, signaling a major push to revolutionize communication for underserved populations.

As AI struggles to separate medical fact from fiction, a new .med domain offers a structural signal of trust, aiming to protect patients and verify sources.

A new partnership aims to tame AI for FinTech with a code-first approach, promising greater governance, agility, and cost savings over rigid SaaS platforms.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new Montreal-based collaboration aims to use advanced AI and a unique dataset to make drug development faster, smarter, and safer for patients.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

Avaí Bio and Austrianova are set to present new findings on a novel cell-based therapy designed to produce the 'longevity protein' Klotho.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

With new clinical trial data showing its AI is superior for complex AFib, Volta Medical heads to a major conference to change the standard of care.

The new algorithm aims to systematically filter out harmful interactions and reduce hidden trading costs in the complex world of off-exchange trading.

A new AI software that analyzes MRI scans has received a first-of-its-kind FDA classification, promising to help doctors differentiate complex brain disorders.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

Canadian energy giant Pembina unveils its '3Cs' strategy, targeting data centers and LNG while promising disciplined 5-7% annual growth for investors.

TriNetX's acquisition of Zetta Genomics' XetaBase platform promises to accelerate research by integrating genomic and clinical data on a global scale.

Montreal's GridBank closes an oversubscribed seed round to build a global marketplace for authentic videos, empowering anyone with a phone to earn passive income.

A new clinical trial uses multi-ancestry genetic risk scores to see if knowing your DNA can motivate you to prevent heart disease. Here's how it works.

A new report reveals a 56-point gap between California's high graduation rate and students' math readiness, threatening both student futures and the state economy.